Elevation Oncology Inc
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable link… Read more
Elevation Oncology Inc (ELEV) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.272x
Based on the latest financial reports, Elevation Oncology Inc (ELEV) has a cash flow conversion efficiency ratio of -0.272x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.71 Million) by net assets ($46.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Elevation Oncology Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Elevation Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Elevation Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elevation Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trinity Biotech plc
NASDAQ:TRIB
|
0.001x |
|
BATT.OIL COR. B DL-0001
F:RAQB
|
N/A |
|
Marygold Companies Inc
NYSE MKT:MGLD
|
-0.040x |
|
Dexin Corporation
TWO:3349
|
0.125x |
|
Telkom
JSE:TKG
|
0.141x |
|
ASEC International Corporation
TWO:6113
|
0.027x |
|
Nirvana Daii Public Company Limited
BK:NVD
|
0.045x |
|
Lithium Universe Limited
PINK:LUVSF
|
N/A |
Annual Cash Flow Conversion Efficiency for Elevation Oncology Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Elevation Oncology Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $60.02 Million | $-36.36 Million | -0.606x | +40.90% |
| 2023-12-31 | $54.81 Million | $-56.18 Million | -1.025x | +41.21% |
| 2022-12-31 | $49.03 Million | $-85.48 Million | -1.743x | -713.12% |
| 2021-12-31 | $140.70 Million | $-30.17 Million | -0.214x | -140.24% |
| 2020-12-31 | $-23.08 Million | $-12.30 Million | 0.533x | -42.58% |
| 2019-12-31 | $-5.87 Million | $-5.45 Million | 0.928x | -- |